Arcturus stock: buy or sell?
December 6th, 2019
Arcturus Therapeutics Ltd. operates as an RNA medicines company. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.
Should I buy Arcturus stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Arcturus stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Arcturus Therapeutics stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 5 ratings published for ARCT stock in the last month. The general sentiment of these ratings is bullish for ARCT stock, with 5 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
Arcturus stock analysis
Arcturus shares broke up the simple moving average line of 100d today and closed at $10.74, rocketed a 9.37%.
Arcturus crossed up the SMA line of 100d today and closed at $10.74. ARCT is retaking the upward trend marking a new rising bottom heading to break out over $11.42.
After boosting an amazing 13.34% in a week last week, Arcturus closed this week at $10.74 and eased a godawful -3.85%. By mid November ARCT collapsed a bloodcurdling -10.08% in just one week.
Since mid June when SMA20w and SMA40w crossed up, ARCT price gained $4.39 per share (69.13%). Since price and SMA40w lines crossed up late May, ARCT climbed $4.51 (72.39%).
Arcturus stock price history
Arcturus IPO was on March 1st, 2012 at $6.00 per share1. Since then, ARCT stock grew a 79.00%, with a yearly average of 11.30%. If you had invested $1,000 in Arcturus stock in 2012, it would worth $790.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Arcturus stock historical price chart
ARCT stock reached 52-week highs on July at $15.50, and all-time highs 2013-10-04 with a price of 188.72.
Arcturus stock price target is $17.30Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' ARCT stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we found 4 price forecasts for Arcturus stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-7||HC Wainwright||Raises Target||$16.00||$18.00||12.5%|
|2019-6-20||Chardan Capital||Set Price Target||n/a||$18.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareArcturus failed experts on March when it posted an Earnings per Share (EPS) of $-0.10 when the market consensus was $-0.62.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Arcturus Therapeutics annual revenues rocketed an exceptional 21.20% to $15.75 M dollars from $13.00 marked in 2017. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) plunged a -54.42% to -138.29%.
|2016||$20 M||-||$-24.60 M-120.7%||-|
|2017||$13 M||-36.23%||$-10.90 M-83.9%||-55.69%|
|2018||$16 M||21.20%||$-21.79 M-138.3%||99.83%|
Quarterly financial resultsArcturus Therapeutics reported $7.58 million in sales for 2018-Q4, a 121.36% up compared to previous quarter. Reported quarter income marked $-1.01 M with a profit margin of -13.34%. Profit margin skyrocketed a 110.90% compared to previous quarter when profit margin was -124.25%. When comparing turnover to same quarter last year, Arcturus sales marked an astounding increase and climbed a 275.10%. Looking back to recent quarterly results, Arcturus Therapeutics posted 3 positive quarters in a row.
|2017-Q2||$4 M||-||$-1.10 M-29.2%||-|
|2017-Q3||$3 M||-12.36%||$-3.18 M-96.4%||189.08%|
|2017-Q4||$2 M||-38.71%||$-5.28 M-261.4%||66.19%|
|2018-Q2||$2 M||18.12%||$-9.95 M-417.0%||88.45%|
|2018-Q3||$3 M||43.46%||$-4.25 M-124.2%||-57.26%|
|2018-Q4||$8 M||121.36%||$-1.01 M-13.3%||-76.23%|
Arcturus ownershipWhen you are planning to buy a company, it's worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Arcturus Therapeutics, 46.92% of all outstanding shares are owned by its staff.
In case of Arcturus stock, 14.51% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ARCT stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Arcturus Therapeutics:
|Market cap||$162.5 M|
|Total shares||15.1 M|
|Float shares||9.3 M|
|- Institutional holdings (%)||14.5%|
|- Insider holdings (%)||46.9%|
|Shares in short selling||0.0%|
|Friday, December 6th, 2019|
|Day range||$9.91 - $11.29|
|Average true range||$0.79|
|50d mov avg||$10.26|
|100d mov avg||$10.73|
|200d mov avg||$8.88|
Arcturus performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We chose as the bechmarking frame for Arcturus Therapeutics stock.